Kornimate/medical-research-clean huggingface dataset:
visual and electromyography assessments in response to train-of-four stimulation of the ulnar nerve

Conditions: Residual Neuromuscular Blockade

Summary: researchers are comparing the accuracy of measuring muscle relaxation during and after surgery with a device that provides numeric value versus visual observation to count of muscle twitches or absence of them by a medical provider monitoring your anesthesia during surgery.


Eligibility criteria:
inclusion criteria: * age \> or = 18 years old * patients willing to participate and provide an informed consent * patients undergoing an elective surgical procedure that requires use of nmba agents administered intraoperatively. exclusion criteria: * patients with disorders, such as stroke, carpal tunnel syndrome, broken wrist with nerve damage, dupuytren contracture, or any similar wrist injury. * patients with systemic neuromuscular diseases such as myasthenia gravis * patients with significant organ dysfunction that can significantly affect pharmacokinetics of neuromuscular blocking and reversal agents, i.e., severe renal impairment or end-stage liver disease. * patients having surgery that would involve prepping the arm or leg into the sterile field

Keywords: neuromuscular blockade tetragraph amg emg
a study of mhe in patients with liver diseases

Conditions: Hepatic Encephalopathy; Minimal Hepatic Encephalopathy; Overt Hepatic Encephalopathy

Summary: the study analyzes the diagnostic efficacy of neurophysiological tests and blood biomarkers on mhe, predicts risk factors on the development of ohe and investigate the mortality of mhe in patients with cirrhosis and acute on chronic liver failure.

hepatic encephalopathy (he) is a common complication and one of the most serious manifestations of cirrhosis and acute on chronic liver failure, not only increasing the risks of death, but also seriously affecting the lives of the patients and their caregivers. minimal hepatic encephalopathy (mhe), the earliest stage of he, despite its undiscernible clinical evidence, it is related with abnormalities of patients' daily cognition, emotion, muscular strength, driving ability, quality of life and socioeconomic status at present. however, mhe is not easy to diagnose in daily clinical work because of time-consuming psychometric tests, especially the inconvenience of application in weak inpatients. this study aims to analyze the diagnostic efficacy of neurophysiological tests and blood biomarkers on mhe, predict risk factors on the development of ohe and investigate the mortality of mhe in patients with cirrhosis and acute on chronic liver failure.

Eligibility criteria:
inclusion criteria: * \>18 years old * cirrhosis * acute on chronic liver failure exclusion criteria: (1) status of ohe; (2) accompanying nervous system diseases, such as dementia or stroke; (3) a history of recent head trauma or surgery, and (4) organic lesions in the brain, such as haemorrhages or infarction; (5) inability to finish the psychometric hepatic encephalopathy score (phes), such as unable to observe patterns or words clearly on paper, and (6) a recent transjugular intrahepatic portosystemic shunt (tips) or abdominal imaging demonstrated portosystemic shunts, and (7) high alcohol consumption (\> 30 g/day in men or 20 g/day in women) or psychoactive medication consumption in the past four weeks.

Keywords: neurophysiologica tests diagnosis minimal hepatic encephalopathy overt hepatic encephalopathy liver cirrhosis acute on chronic liver failure blood biomarkers
viaskin® peanut (dbv712) expanded access protocol

Conditions: Peanut Allergy

Summary: this is an open label expanded access program for male and female patients ≥ 4 years old.

this study is an open-label intermediate-size eap designed to provide treatment access for eligible peanut-allergic children. this eap entails visits every three months to assess patient status, safety, and to provide drug supply. viaskin® peanut treatment will continue until, in the clinical judgment of the investigator, the patient is no longer benefiting from continuation of the treatment, the drug becomes approved and available by prescription, or the study is terminated.

Eligibility criteria:
inclusion criteria: * male or female ≥ 4 years of age * prior participation in a viaskin® peanut realise or people clinical study for peanut-allergic patients exclusion criteria: * pregnancy or lactation or planning a pregnancy. * generalized dermatologic disease (for example, active atopic dermatitis, uncontrolled generalized active eczema, ichthyosis vulgaris) extending widely on the skin and especially on the back with no intact zones to apply the viaskin® patches. * patients who developed hypersensitivity to excipients of the viaskin® patches. * received or planning to receive anti-tumor necrosis factor drugs or anti-ige drugs (such as omalizumab) or any biologic immunomodulatory therapy. * receiving or planning to receive any other type of immunotherapy to any food (for example, epit, oit, or slit or specific oral tolerance induction) or any aeroallergen or venom immunotherapy during their participation in the study. * use of cyclosporine or other immunosuppressive agents within 3 months before entering the study. topical calcineurin inhibitors are permitted. * a history of important non-compliance during the realise or people studies. important non-compliance includes patients not applying the patches for 60 or more days in total and/or for 30 or more consecutive days during the realise or people studies.

Keywords: peanut allergy epit epicutaneous immunotherapy viaskin®
kids diabetes telemedicine study (kites)

Conditions: Type 1 Diabetes

Summary: randomised prospective single-center clinical trial evaluating the outcomes of children with type 1 diabetes followed up by remote telemedicine check-ups without their personal present at the outpatient clinic.

at the first study visit (visit month 0), after obtaining the written informed consent from the parents, 50 children with type 1 diabetes will be randomised to two groups of equal size. the first group will have regular visits with their diabetologist to our outpatient clinic every 3 months (visits month 3 and month 6), the second group will have a remote control by email only instead of regular visits (visits month 3 and month 6). the cgm data and inzulin dose will be evaluated through cloud systems (diasend, carelink) at every control by diabetologist. the patients would be instructed about the reccomendation during the "live" control or by email according the group. the final meeting (visit month 9) will take place at our outpatient clinic for both of the study groups. the cgm data, hba1c, and the questionaire evaluating the quality of the controls will be evaluated.

Eligibility criteria:
inclusion criteria: * diagnosis of type 1 diabetes * age 1-18 years * type 1 diabetes duration at least 12 months * using continuous glucose monitoring for at least previous 6 months * willingness to use continuous glucose monitoring for the whole study * signed informed consent by the legal representatives exclusion criteria: * change of the type 1 treatment modalitry (from insulin pens to insulin pump or vice versa, start the treatment with hybrid closed loop, start of the treatment with the drug affecting the glucose metabolism) in 3 months prior to the study or planning to change the treatment modality during the study * concomitant psychiatric diagnosis diagnosed by the psychiatrist * hospitalisation for severe hypoglycaemia and/or diabetic ketoacidosis in 1 year prior to the study initiation * glycated hemoglobin concentration \>90 mmol/mol in 1 year prior to the study or substantially bad co-operation of the patient/parent

Keywords: type 1 diabetes children telemedicine virtual clinic
universal hiv screening and targeted hcv screening in emergency department

Conditions: Hepatitis C; Hiv

Summary: cross-sectional study of patients consulting in the emergency room of the centre hospitalier de l'université de montréal (chum), to assess the implementation of an "opt-out" screening program for hiv and hcv and prospective follow-up for 3 months of positive cases.

the purpose of this study is to evaluate the feasibility of routine hiv and hcv screening using an "opt-out" approach at the emergency room of the chum and to determine the rate of new positive hiv and hcv cases. a sub-analysis will focus more specifically on hcv in the quebec equivalent of "baby boomers" (1945-1975) since this is the group that was targeted in the united states. the second phase of this study will evaluate the effectiveness of the linkage to the healthcare system for people diagnosed with hiv or hcv and how fast these people are taken care of and put on treatment.

Eligibility criteria:
inclusion criteria: * individuals attending the emergency room of the centre hospitalier de l'université de montréal exclusion criteria: * individuals unable to opt-out due to their psychological or physical condition

Keywords: screening linkage to care
determine the effect of prone positioning in adults with ards by electrical impedance tomography

Conditions: ARDS; Prone Position; Electrical Impedance Tomography

Summary: determine the effect of prone positioning on ventilation and perfusion distribution in adults with acute respiratory distress syndrome by electrical impedance tomography

by intravenous injection of a small amount of normal saline, electrical impedance tomography enables evaluation of the pulmonary blood flow. eit might be helpful in establishing the hypoxemia etiology at bedside via combining regional ventilation and perfusion information. the objective of this study was to describe the physiological effects of prone position on respiratory mechanics, ventilation and pulmonary perfusion in patients with ards.

Eligibility criteria:
inclusion criteria: * patients who were undergoing mechanical ventilation with moderate-to-severe ards (defined as a pao2:fio2 ratio \< 150 mm hg with a positive end-expiratory pressure ≥ 5 cm of water, and an fio2 of ≥ 0.6) according to the berlin definition exclusion criteria: * contraindications to the use of eit (e.g., presence of pacemaker or chest surgical wounds dressing)
screening protocol

Conditions: Glaucoma

Summary: the objective of this study is to collect data for the development and validation a screening process using aggregate data. in this study, data collection will encompass both retrospective and prospective approaches across multiple sites in the united states.


Eligibility criteria:
inclusion criteria: * subjects 22 years of age or older on the date of data collection (retrospective) or informed consent (prospective). * for prospective data collection or missing retrospective data collection, subjects able to understand the written informed consent and willing to participate as evidenced by signing the informed consent. * bcva 20/40 or better (each eye). exclusion criteria: * for prospective or missing retrospective data collection, subjects unable to tolerate ophthalmic testing. * concomitant diseases known to affect the visual field: history of leukemia, dementia, parkinson's disease, alzheimer's disease, stroke, or autoimmune diseases. * history of intraocular surgery (uncomplicated cataract or glaucoma surgeries are accepted) * ocular findings or history of co-morbidities, including, but not limited to: uveitis, non-glaucomatous optic neuropathy, trauma, retinal detachment, vein or artery occlusions, wet age-related macular degeneration, geographic atrophy, proliferative diabetic retinopathy, vitreous hemorrhage, severe cataract, severe non-proliferative diabetic retinopathy. controlled diabetes and hypertension participants can be included. * unreliable vf testing and/or poor-quality oct scans. * poor fixation.
comparison of two biological aortic valves. mosaic ultra and trifecta.

Conditions: Aortic Valve Stenosis

Summary: comparing two biological valves in a prospective randomized study. mosaic ultra and trifecta. the investigators are looking at eoa and the pressure gradients over the valve by patients with the same annulus measured by a hegar dilatator.


Eligibility criteria:
inclusion criteria: * aortic valve disease exclusion criteria: 1. pregnant 2. breast feeding 3. aortic valve bigger than 23 mm 4. endocarditis 5. ef \< 50%

Keywords: eoa
cisplatin with gemcitabine with dexamethasone in patients with aggressive non-hodgkin's lymphoma

Conditions: Non-Hodgkin's Lymphoma

Summary: the purpose of this study it to evaluate efficacy of gemcitabine with cisplatin and dexamethasone in patients with aggressive non-hodgkin's lymphoma who have previously progressed on first line of chemotherapy with anthracyclines.


Eligibility criteria:
inclusion criteria: * the patients must have a histological diagnosis of aggressive non-hodgkin's lymphoma including the following sub-categories of the who classification: * diffuse large b-cell lymphoma and its variants (immunoblastic, burkitt-like, sclerosis of mediastinum, large b-cell malt, rich in t-cells and anaplastic b-cell lymphoma) * peripheral t-cell lymphoma * anaplastic lymphoma of large t-cells /null cells * patients are eligible if they have documented evidence of progression after prior first-line chemotherapy containing anthracyclines associated or not with rituximab. patients with refractory disease to first line of treatment are also eligible. * ecog ps (performance status) less than or equal to 2 * presence of bidimensionally measurable disease in accordance with who criteria. exclusion criteria: * involvement of the cns. * any medical condition which contraindicates the degree of hydration required for the safe use of cisplatin. * intermediate degree lymphoma derived from the malignant transformation of a previous low-grade lymphoma. * active infection (in the opinion of the investigator).
bucye conditioning regimen for pcnsl undergoing auto-hsct

Conditions: Primary Central Nervous System Lymphoma; Autologous Hematopoietic Stem Cell Transplantation; Conditioning

Summary: the purpose of this study is to evaluate the safety and efficacy of bucye conditioning regimens in primary central nervous system lymphoma undergoing autologous hematopoietic stem cell transplantation.

the prognosis of patients with primary central nervous system lymphoma (pcnsl) is poor. recent studies have demonstrated that autologous hematopoietic stem cell transplantation (auto-hsct) could improve the prognosis of these patients. however, the optimal conditioning regimen of auto-hsct remains unclear. in this study, the investigators evaluated the safety and efficacy of bucye conditioning regimens in pcnsl undergoing auto-hsct.

Eligibility criteria:
inclusion criteria: * primary central nervous system lymphoma patients * achieving cr or pr, then mobilizing and collecting of peripheral blood stem cells exclusion criteria: * any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure) * patients with any conditions not suitable for the trial (investigators' decision)
validation study of the sagit® instrument in acromegaly

Conditions: Acromegaly

Summary: patients will be treated in accordance with the standard medical practice of the hospital where they have been recruited during their participation in this study. no additional assessments or tests will be required. sagit® is a new instrument developed by a group of acromegaly experts to help practicing endocrinologists to manage acromegalic patients and disease activity in their clinical practice and define acromegaly staging. it reports 5 elements: signs and symptoms - s; associated comorbidities - a; growth hormone (gh) concentration - g; insulin-like growth factor 1(igf-1) concentration -i; tumour size- t. the instrument has been pre evaluated during a qualitative pilot study. the purpose of the validation study is to define and validate the scoring of the sagit® instrument.


Eligibility criteria:
inclusion criteria: * male or female aged 18 years-old or above at study inclusion * treatment-naïve and non treatment-naïve patients with a diagnosis of acromegaly * data required to complete the sagit® tool are available in the patient medical records and do not require additional assessments or tests * data required to complete the sagit® tool are recorded within the 3 months preceding the inclusion visit (6 months for mri) exclusion criteria: * acute uncontrolled disease requiring intensive care
changes of pulse pressure variation duing tidal volume challenge in patients with spontaneous breathing

Conditions: Hemodynamic Monitoring

Summary: background: predicting preload responsiveness by using dynamic indicators before administering fluids to critically ill patients is nowadays routinely performed at the bedside. unlike other dynamic indicators of preload responsiveness that require cardiac output monitoring, pulse pressure variation (ppv) can be simply obtained via an arterial catheter . however, ppv is not reliable in mechanically ventilated patients with spontaneous breathing activity. we hypothesized that an increase in ppv after a tidal volume (tv) challenge (tvc) or a decrease in ppv during passive leg raising (plr) will predict preload responsiveness in such cases. objective: to examine if the change in ppv during plr and after a tvc can predict preload responsiveness in patients with mechanical ventilation and persistent spontaneous breathing

prospective non interventional study conducted in two intensive care units. patients under mechanical ventilation with spontaneous cycles, for whom the physician in charge decided to test preload responsiveness were included. we collected demographic and clinical information, the use of mechanical ventilation and its parameters, the use of vasopressors and their dosage and blood lactate. firstly, transthoracic echocardiography (tte) was performed to measure the velocity time integral (vti) of the left ventricular outflow tract . a plr maneuvre is performed with tte probe in place and a new assessement of vti is measured, in addition to the ppv and other hemodynamic parmeters (diastolic, mean and systolic arterial pressure, heart rate, cvp). delta vti is the difference between vti during plr and vti at baseline divided by vti at baseline. patients were considered as preload responsive when delta vti was ≥10%. secondly, a tvc was performed by increasing the tv by 2ml/kg predicted body weight from its baseline value . ppv was recorded before and after the tvc in addition to the other hemodynamic parmeters listed above. further more, respiratory parameters are collected: ventilator setting, plateau pressure, upper airway pressure, before and during the tvc.

Eligibility criteria:
inclusion criteria: * adult critically ill patients if the clinicians in charge decided to test preload responsiveness because of mean arterial pressure (map) \< 65 mmhg (measured by an arterial catheter) or other symptoms of acute circulatory failure (e.g. oliguria, skin mottling, tachycardia, hyperlactatemia) exclusion criteria: * arrythmia * no spontaneous breathing * difficult condition for tansthoracic echocardiography
effect of pterostilbene on cholesterol, blood pressure and oxidative stress

Conditions: Hyperlipidemia; Blood Pressure; Oxidative Stress

Summary: pterostilbene is one of several stilbenes found in certain berries, particularly blueberries, that have demonstrated pre-clinical benefit to cholesterol, blood pressure, and oxidative stress. the purpose of this study is to evaluate whether pterostilbene will help control cholesterol and blood pressure, as well as improve markers for oxidative stress in patients with dyslipidemia meeting inclusion criteria. the investigators also want to look at the safety of pterostilbene in these patients.

subjects will be divided into one of four groups: (1) pterostilbene 50 mg twice daily; (2) pterostilbene 125 mg twice daily; (3) pterostilbene 50 mg/grape extract 100 mg twice daily; (4) matching placebo twice daily taken either one hour before or two hours after a meal. blood and urine will be collected at enrollment and final study visits. if the patient's low density lipoprotein-c (ldl-c) or total cholesterol (tc) is not within the inclusion criteria based on enrollment blood drawn, the patient will not be allowed to initiate study medication. all study visits will consist of brief clinical examination (including vital signs), subjective adverse event reporting, and fasting donated blood and urine for clinical laboratory tests. pill counts will be done to assess compliance.

Eligibility criteria:
inclusion criteria: * patients ≥18 years of age with a previous tc ≥200 mg/dl and/or a ldl ≥100 mg/dl on either no therapy or stable therapy * any concomitant cholesterol medication (not listed in the exclusion criteria) must be at a stable dose for at least 2 months prior to baseline laboratory exclusion criteria: * patients with significant hepatic, renal or gastrointestinal tract disease * receiving thiazolidinediones or fibric acid derivatives * current overt cardiovascular disease * women of reproductive potential not receiving birth control * pregnant/nursing women

Keywords: hyperlipidemia cholesterol blood pressure oxidative stress pterostilbene blueberry grape extract
immune reconstitution to measles virus of hiv infected children in zambia

Conditions: Measles

Summary: this is an observational study of hiv-1 infected children starting antiretroviral therapy to measure the magnitude and quality of general immune reconstitution and pathogen-specific immune reconstitution to measles virus.

this is a prospective, observational cohort study of 230 hiv-1-infected children initiating art at public clinics in lusaka, zambia to measure the magnitude and quality of general immune reconstitution and pathogen-specific immune reconstitution to measles virus. non-specific immune reconstitution will be assessed by serial measurements of the number and percentages of cd4+ and cd8+ t-lymphocytes, number and percentages of activated cd4+ and cd8+ t-lymphocytes (using cell surface staining for hla-dr and cd38), changes in the proportions of naïve and memory cd4+ and cd8+ t-lymphocyte subsets (using cell surface staining for cd45ra and ccr7), and changes in thymic output as determined by trec levels. virologic responses to art will be assessed by serial measurements of plasma hiv-1 rna levels. within the observational study, there is a nested study of revaccination against measles virus of hiv-1-infected children receiving art who lack protective antibody titers to assess the proportion of revaccinated children who develop protective immunity and the duration of protective immunity. anti-measles virus igg antibodies will be measured 9 months after initiation of art. the results will be available at the 12-month follow-up visit and measles revaccination will be recommended to those children lacking protective antibody levels to measles virus.

Eligibility criteria:
inclusion criteria: * boys and girls 9 months to 10 years of age residing in lusaka, zambia are eligible for enrolment. * initiating art * history of measles vaccination confirmed by examination of the immunization card.

Keywords: hiv art children